Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emacizumab (ivarmacitinib) plus csDMARDs for systemic sclerosis
ChiCTR2600126810Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in systemic sclerosis (SSc) comparing Ivarmacitinib + csDMARDs with Placebo + csDMARDs (2 arms). Primary endpoint: Modified Rodnan Skin Score (mRSS). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on ChiCTR2600126810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126810.